General MedicationsNASALGeneric
NOCTIVA
DESMOPRESSIN ACETATE
Standard Dose
0.00166MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview NOCTIVA is listed in Drugs@FDA under application 201656 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DESMOPRESSIN ACETATE Form and strength SPRAY, METERED;NASAL - 0.00166MG/SPRAY Sponsor ACERUS PHARMS Submission history Latest submission status date: 2017-03-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview NOCTIVA is listed in Drugs@FDA under application 201656 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DESMOPRESSIN ACETATE Form and strength SPRAY, METERED;NASAL - 0.00166MG/SPRAY Sponsor ACERUS PHARMS Submission history Latest submission status date: 2017-03-03 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.